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ABSTRACT
Understanding the role of the microbiota in health and 
disease may offer new insights into the factors that start 
and drive the progression of various diseases, like autism, 
auto-immune disease, obesity, diabetes, and cancer. In 
turn, this will offer a platform to stratify the risk of patients 
for complications and also to deliver new personalised 
therapeutic strategies.
INTRODUCTION
Lederberg and McCray1 first defined the term microbiota to 
describe the microorganisms that live in or on the human 
body. Such microorganisms are found on the skin and in the 
eyes, gut, mouth, and vagina. About two-thirds of the human 
microbiota is hosted in the gastrointestinal tract, which is the 
largest interface to the external environment.
Approximately 1 kg of bacteria is hosted in the human 
gut! Overall, that equates to about 9.9 million bacterial genes, 
with the ratio of host DNA to microbiome DNA being 1:10. 
It is worth mentioning that these microorganisms are also 
present earlier in life, in the infant gut. Specifically, research 
has shown that, during delivery, the infant gut is colonised 
by the microbiome of the maternal anus, skin, and vagina. 
In addition, the infant gut is inhabited by the bacteria the 
neonate is exposed to after birth.2 Other factors structure the 
neonatal microbiome in both animal models and humans, 
including antibiotic treatment and diet.3
It is posited that microbiota co-evolved in a mutual 
relationship with humans. In fact, emergent evidence 
supports the hypothesis that these microorganisms play an 
important role in maintaining immunologic, metabolic, 
and nutritional homeostasis in our bodies. However, there 
are both beneficial and harmful bacteria. Eubiosis occurs 
if the beneficial bacteria dominate. In contrast, dysbiosis 
occurs when the harmful bacteria take over. One of the most 
common diseases caused by dysbiosis is infection.4 In some 
specific cases of dysbiosis, consuming live microorganisms in 
probiotics may improve or restore the gut flora.
In order to understand these host–microbe interactions, 
researchers use gnotobiotic animal models; animals in which 
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the bacterial strains and other microorganisms present are 
known. Studies in both these animal models and humans 
have associated microbiome signatures with disease and 
health. Indeed, advances in microbial research have provided 
insight into the role of the human microbiota in diseases such 
as autism, auto-immune disease, cancer, obesity and diabetes. 
In turn, all of this knowledge will offer a platform to deliver 
new personalised therapeutic strategies in the near future.
AUTISM SPECTRUM DISORDERS (ASD)
In recent years, it has become evident that our gut microbiota 
has far-reaching implications for our brain development and 
function.  Dysbiosis in the gut have been linked with mood 
disorders (e.g. depression) and autism spectrum disorders 
(ASD).5 Even though genetic inheritance has a role in 
developing ASD, external influences such as gut microbiota 
may be equally important. While a cause-effect association 
has not yet been identified, many gastrointestinal problems 
including abdominal pain, constipation, and diarrhoea are 
often concomitant with ASD.6 Indeed, increasing evidence 
suggests bi-directional communication between the gut 
microbiota and the central nervous system (known as the 
“gut-brain axis”), which may play a role in ASD pathogenesis.
The interplay between gut microbiota and ASD may 
begin even before birth: factors such as diabetes, maternal 
obesity, and the taking of antibiotics, affect the pre-birth 
baby gut microbiota, and may be associated with ASD 
development. Other neonatal factors, such as birth delivery 
mode (vaginal vs. caesarean section) and breast-feeding 
affect gut microbiota diversity and the risk of developing 
ASD. For example, breast-feeding infants for >6 months 
has been related to a decreased risk of developing ASD,7 
whereas the risk is increased in children born by caesarean 
section.8 Indeed, the gut microbiota of children with ASD is 
typically of a different composition and diversity than that of 
children without ASD.9
Our understanding of the gut microbiota-ASD 
relationship has greatly improved. As a result, emergent 
potential therapies for ASD are increasingly focused on 
gut microbiota modulation. These have included the use of 
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prebiotics, probiotics, or diet changes in animal models and 
ASD individuals. Other possible therapies include faecal 
microbiota transplantation, which involves delivering faecal 
microbiota from healthy individuals to those with dysbiotic 
gut microbiota. Overall, changing the gut microbiota 
might one day provide effective and risk-free therapies for 
ASD individuals.
OBESITY AND DIABETES
In both developed and developing nations, obesity is 
associated with a higher risk for chronic diseases. In 
particular, it is postulated that obesity is linked with 
chronic, low-grade inflammation which originates from the 
adipose tissue and the gut and then spreads to other areas 
of the body. In the gut, the dysregulation of microbiota 
can increase endotoxin exposure. In addition, the intestine 
- a barrier against harmful substances from the external 
environment - can be compromised by factors such as 
diet, exercise, gastrointestinal peptides, inflammatory 
cytokines, and pathogens.
In this regard, Pei et al.10 have shown that lipid profiles, 
intestinal barrier function, and innate and adaptive immune 
responses can be improved by consuming yoghurt. Yoghurt, 
which is dense in nutrients, can decrease inflammation 
and enhance gut health. Therefore, while yoghurt benefits 
individuals with constipation and diarrheal diseases, and 
those with cardiovascular diseases, hypertension, and 
lactose intolerance, it also improves the health of obese and 
diabetic people.
In obese and type 2 diabetic mice, Everard et al. 
(2014) showed that the probiotic yeast Saccharomyces 
boulardii alters gut microbiota and decreases metabolic 
features, such as fat mass development, hepatic steatosis, 
and low-grade inflammation.11 Similarly, Balakumar et 
al. (2018)12 investigated the effect of probiotics of Indian 
gut origin (Lactobacillus spp.) in mice and found that 
in high-fat diet mice, the probiotic intervention resisted 
insulin-resistance and diabetes. In general, this could 
lead to different probiotic treatments in the future.
AUTO-IMMUNE DISEASES
It is known that the gut microbiota plays a role in 
the development of the lymphoid system.13 In fact, 
dysbiosis of gut microbiota also occurs in patients with 
autoimmune diseases such as Hashimoto’s thyroiditis, 
systemic lupus erythematosus, systemic sclerosis, as well 
as type 1 diabetes mellitus.
Hashimoto’s thyroiditis, or HT, is an organ-specific 
disorder in which both environmental factors and 
genetic predisposition are disease triggers. Zhao et al. 
(2018)14 performed a systematic comparative analysis 
of the gut microbiota in HT patients and healthy 
controls and revealed that HT patients have altered gut 
microbiota. They also showed that gut microbiota is 
associated with clinical parameters, therefore suggesting 
that the composition of the microbiome could be used 
in disease stratification.
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Systemic lupus erythematosus is another autoimmune 
disease. It is a complex disorder with no known cure, 
characterised by persistent inflammation. Mu et al. (2017)15 
recently reported that in lupus, the gut microbiota is involved 
in the pathogenesis of renal dysfunction. Mu et al. used a 
model of lupus nephritis and found a significant depletion 
of Lactobacillales in the gut microbiota. Intriguingly, 
increasing the Lactobacillales in the gut enhanced renal 
function and extended survival in mice. Although 
promising, future studies will determine whether this can be 
replicated in humans.
CANCER
Over a quarter of a million people each year develop 
colorectal cancer (CRC). CRC is fundamentally a genetic 
disease. Specifically, there is an accumulation of mutations 
in oncogenic genes that foster autonomous colonic epithelial 
cell proliferation, which over 10 to 40 years, results in 
colon adenomas. A small number of these adenomas, in 
some individuals, progress to cancer. Although, it is still 
unknown what events precipitate the initial mutation(s) 
or the later progression from adenomas to cancer, the gut 
microbiome is a main suspect. Indeed, one finds several 
attempts to associate individual bacterial microbes with 
CRC in humans.16,17 Some, based on the ‘keystone species’ 
concept, argue that a microbial leader recruits other microbes 
and these start the fostering events of CRC.18-20 Thus, it 
is proposed that over the years, several microbes may be 
involved and their metabolic activities interact with the host 
diet, ingested pharmaceuticals, or physiology.
An example of such interplay between the host and 
gut microbes is observed in bile acid metabolism. The 
liver secretes the conjugated bile acids, cholic acid and 
chenodeoxycholic acid. Bacteria can deconjugate these 
conjugated bile acids producing lithocholic acid and 
deoxycholic acid. These secondary bile acids are the two 
principal faecal bile acids and it has been proposed that 
they may contribute to carcinogenesis. Indeed, back in 
2002, Reddy21 already showed that these faecal bile acids are 
increased in diets rich in saturated fats and are associated 
with higher incidence of CRC. Gill and Rowland22 studied 
the correlation of dietary fat intake and CRC risk and found 
that CRC patients, when compared to healthy controls, had 
elevated faecal lithocholic and deoxycholic acid. Lithocholic 
and deoxycholic acid were thus proposed that they may be 
pro-carcinogenic bacterial metabolites. This proposition still 
stands today and recent studies have shown that they can be 
pro-inflammatory through the production of reactive oxygen 
and nitrogen species and NF-κB activation in the cells of 
intestinal epithelia.23 In 2018 Le Gall et al.24 showed that CRC 
patients had increased faecal concentrations of branched 
chain fatty acids, besides other potential metabolites that may 
be responsible for carcinogenesis. 
The exact mechanism by which the unconjugated 
bile acids are responsible for carcinogenesis is still being 
researched. Barrasa et al.25 showed in vitro that chronic 
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exposure to deoxycholic acid causes DNA adduct, decreases 
apoptosis, and augments epithelial cell proliferation. In 2016 
Farhana et al.26 proposed that the unconjugated secondary bile 
acids modulate muscarinic 3 receptor and Wnt/β-catenin signals 
and cause cancer stem cells in the epithelial cells of the colon.  
However, gut microbiota can also have positive effects on 
the host physiology. One mechanism is in promoting anti-
tumour immunity. Sivan et al.27 studied melanoma growth in 
mice and found that the commensal Bifidobacterium promotes 
anti-tumour immunity. Indeed, Bifidobacterium alone, given 
orally, controlled tumour growth to the same extent as antibody 
therapy with programmed cell death ligand 1 (PD-L1) (a check 
point blockade type of immunotherapy). Similarly, Spranger et 
al.28 clinically found that some cancer patients fail to respond 
to immunotherapy. This could be due to lack of activated 
T-cell infiltration inside the tumour microenvironment. They 
propose that intersubject heterogeneity might be responsible 
and includes variations in the mutations of specific oncogene 
pathways. But it may also be due to environmental factors 
like the commensal microbial composition. This has clinical 
utility in that, by manipulating the gut microbiota, one might 
modulate cancer immunotherapy and increase the number of 
patients that respond.
CONCLUSION
Overall, recent research has demonstrated that keeping your 
gut flora healthy has extensive implications. Though still an 
emerging field, the gut microbiota may be playing important 
roles in autism, auto-immune disease, cancer, obesity and 
diabetes. As a result, research efforts are being focused on 
developing gut microbiota modulation therapies and using 
the microbiome for diagnosis and treatment stratification. 
Hippocrates might have been right when he said that ‘All disease 
begins in the gut’ and ‘Let food be thy medicine’.
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